A Short Course of Celecoxib Prevents Heterotopic Ossification Following Cementless Total Hip Arthroplasty

Overview

Journal Life (Basel)

Specialty Biology

Date 2023 Apr 28

PMID 37109473

Authors

Hamid Al Badi

Michael Tanzer

Anas Nooh

Brandon Hall

Adam Hart

Affiliations

Soon will be listed here.

Abstract

Heterotopic ossification (HO) is a common complication after total hip arthroplasty (THA) and can result in pain and loss of motion of the hip. This is the first study in the literature to determine if a short course of Celecoxib is effective in the prevention of HO in patients undergoing cementless THA. In this retrospective study of prospectively collected data, consecutive patients undergoing a primary cementless THA were reviewed at a 2-year follow-up. The Control group consisted of 104 hips that did not receive Celecoxib (Control group), while the 208 hips in the Celecoxib group received 100 mg twice daily for 10 days. Radiographs, patient-recorded outcome measures and range of motion (ROM) were evaluated. Overall, there was a significantly decreased incidence of HO in the Celecoxib group (18.7%) than in the Control group (31.7%) ( = 0.01). The odds that a patient developed HO using Celecoxib were 0.4965 times the odds that a patient developed HO without treatment. Clinically, the Celecoxib group demonstrated significantly greater improvement in their mean WOMAC stiffness (0.35 vs. 0.17, = 0.02) and physical function scores (3.26 vs. 1.83, = 0.03) compared to those in the Control group, but there was no difference in the ROM between the two groups. This study is the first to demonstrate that the lowest dose of Celecoxib for a short course of only 10 days is a simple and effective prophylactic treatment option that can significantly reduce the incidence of HO following cementless THA.

Citing Articles

Heterotopic ossification (HO) prophylaxis in total hip arthroplasty (THA): A systematic review of level I and level II evidence since 2000.

Puga T, Box M, Dieu V, Marchese C, Riehl J Bone Rep. 2025; 24:101828.

PMID: 39935784 PMC: 11810696. DOI: 10.1016/j.bonr.2025.101828.

Ectopic calcifications in the musculoskeletal field: the basis for preventive and curative pharmacological strategies.

Milovanovic P, Savic I, Popovic A, Grajic M Clin Rheumatol. 2025; 44(3):869-886.

PMID: 39853559 DOI: 10.1007/s10067-025-07335-w.

References

Kjaersgaard-Andersen P, Nafei A, TEICHERT G, Kristensen O, Schmidt S, Keller J . Indomethacin for prevention of heterotopic ossification. A randomized controlled study in 41 hip arthroplasties. Acta Orthop Scand. 1993; 64(6):639-42. DOI: 10.3109/17453679308994587. View

Risto O, Wahlstrom O, Abdiu A . The effect of low dose diclofenac sodium administered locally on heterotopic bone formation in rats. Int Orthop. 1995; 19(6):392-5. DOI: 10.1007/BF00178357. View

Eggli S, Woo A . Risk factors for heterotopic ossification in total hip arthroplasty. Arch Orthop Trauma Surg. 2001; 121(9):531-5. DOI: 10.1007/s004020100287. View

Pagnani M, Pellicci P, Salvati E . Effect of aspirin on heterotopic ossification after total hip arthroplasty in men who have osteoarthrosis. J Bone Joint Surg Am. 1991; 73(6):924-9. View

Smalley W, Griffin M . The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Gastroenterol Clin North Am. 1996; 25(2):373-96. DOI: 10.1016/s0889-8553(05)70253-3. View

Lavernia C, Contreras J, Villa J, Rossi M . Celecoxib and heterotopic bone formation after total hip arthroplasty. J Arthroplasty. 2013; 29(2):390-2. DOI: 10.1016/j.arth.2013.06.039. View

Ray W, Stein C, Daugherty J, Hall K, Arbogast P, Griffin M . COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 2002; 360(9339):1071-3. DOI: 10.1016/S0140-6736(02)11131-7. View

McConnell S, Kolopack P, Davis A . The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): a review of its utility and measurement properties. Arthritis Rheum. 2001; 45(5):453-61. DOI: 10.1002/1529-0131(200110)45:5<453::aid-art365>3.0.co;2-w. View

Naylor B, Iturriaga C, Bisen Y, Caid M, Reinhardt K . Heterotopic Ossification Following Direct Anterior Total Hip Arthroplasty With and Without Postoperative Analgesic Nonsteroidal Anti-inflammatories. J Arthroplasty. 2021; 36(10):3471-3477. DOI: 10.1016/j.arth.2021.05.017. View

10.

Healy W, Lo T, Covall D, Pfeifer B, Wasilewski S . Single-dose radiation therapy for prevention of heterotopic ossification after total hip arthroplasty. J Arthroplasty. 1990; 5(4):369-75. DOI: 10.1016/s0883-5403(08)80097-6. View

11.

Leese P, Hubbard R, Karim A, Isakson P, Yu S, Geis G . Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol. 2000; 40(2):124-32. DOI: 10.1177/00912700022008766. View

12.

ACKERMAN L . Extra-osseous localized non-neoplastic bone and cartilage formation (so-called myositis ossificans): clinical and pathological confusion with malignant neoplasms. J Bone Joint Surg Am. 1958; 40-A(2):279-98. View

13.

Nilsdotter A, Bremander A . Measures of hip function and symptoms: Harris Hip Score (HHS), Hip Disability and Osteoarthritis Outcome Score (HOOS), Oxford Hip Score (OHS), Lequesne Index of Severity for Osteoarthritis of the Hip (LISOH), and American Academy of Orthopedic.... Arthritis Care Res (Hoboken). 2012; 63 Suppl 11:S200-7. DOI: 10.1002/acr.20549. View

14.

Konski A, Weiss C, ROSIER R, Poulter C, Pelligrini V, Anthony P . The use of postoperative irradiation for the prevention of heterotopic bone after total hip replacement with biologic fixation (porous coated) prosthesis: an animal model. Int J Radiat Oncol Biol Phys. 1990; 18(4):861-5. DOI: 10.1016/0360-3016(90)90408-c. View

15.

Burd T, Lowry K, Anglen J . Indomethacin compared with localized irradiation for the prevention of heterotopic ossification following surgical treatment of acetabular fractures. J Bone Joint Surg Am. 2001; 83(12):1783-8. DOI: 10.2106/00004623-200112000-00003. View

16.

Ware Jr J, Kosinski M, Keller S . A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996; 34(3):220-33. DOI: 10.1097/00005650-199603000-00003. View

17.

Knelles D, Barthel T, Karrer A, Kraus U, Eulert J, Kolbl O . Prevention of heterotopic ossification after total hip replacement. A prospective, randomised study using acetylsalicylic acid, indomethacin and fractional or single-dose irradiation. J Bone Joint Surg Br. 1997; 79(4):596-602. DOI: 10.1302/0301-620x.79b4.6829. View

18.

Naraghi F, DeCoster T, Moneim M, Miller R, Rivero D . Heterotopic ossification. Orthopedics. 1996; 19(2):145-51. DOI: 10.3928/0147-7447-19960201-10. View

19.

Lo T, Healy W, Covall D, DOTTER W, Pfeifer B, TORGERSON W . Heterotopic bone formation after hip surgery: prevention with single-dose postoperative hip irradiation. Radiology. 1988; 168(3):851-4. DOI: 10.1148/radiology.168.3.3136510. View

20.

Vielpeau C, Joubert J, Hulet C . Naproxen in the prevention of heterotopic ossification after total hip replacement. Clin Orthop Relat Res. 1999; (369):279-88. DOI: 10.1097/00003086-199912000-00029. View